Evox Therapeutics Valuation, Funding & Investors

Shape Therapeutics is a Seattle-headquartered biotechnology company pioneering RNA editing and gene therapy platforms. Its technologies address neurodegenerative disorders, metabolic conditions, and rare genetic diseases through advanced payloads, delivery systems, and manufacturing processes.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.

Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS. Its activities are conducted across Australia, the United States, Hong Kong, and Moldova through global clinical development programs and strategic research collaborations.

Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. The company's segments include the Drug Development segment and the Other segment.

New Radiomedicine Technology is a Chengdu-headquartered provider of medical isotopes for malignant tumor diagnosis and treatment, located in Shuangliu Western Airport Development District. Chengdu New Radiomedicine Technology Co., Ltd., founded in April 2016, researches, manufactures, and sells radiopharmaceuticals while offering technology consulting via nrtmedtech.com.

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.

Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.

TrueBinding is a biotherapeutics developer targeting immuno-oncology and other unmet medical needs. The Cambridge, United Kingdom-based company employs its proprietary Truebinding platform to identify novel ligands for checkpoint inhibitor receptors, resulting in six previously uncharacterized molecules.